{"id":1077,"date":"2019-04-29T15:51:49","date_gmt":"2019-04-29T07:51:49","guid":{"rendered":"http:\/\/www.bioactivescreeninglibrary.com\/?p=1077"},"modified":"2022-01-07T10:53:12","modified_gmt":"2022-01-07T02:53:12","slug":"dur3-sam3-main-contributors-polyamine-uptake-highdose-cisplatin-chemotherapy","status":"publish","type":"post","link":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/2019\/04\/29\/dur3-sam3-main-contributors-polyamine-uptake-highdose-cisplatin-chemotherapy\/","title":{"rendered":"DUR3 and SAM3 are the main contributors to polyamine uptake during highdose cisplatin chemotherapy"},"content":{"rendered":"<p>With regard to tumor type, we found that individuals with esophageal cancer were at a significantly higher risk for cisplatininduced nephrotoxicity than were those with lung cancer. To our knowledge, such an association has not previously been described. The median dosage of cisplatin in patients with esophageal cancer was 70 mg\/m2, which was not higher than that overall. Moreover, whereas most patients with esophageal cancer in our analysis were treated with cisplatin together with 5-fluorouracil as the standard care, this regimen was also administered to patients with gastric or head and neck cancer. A difference in dosage or in the combination of chemotherapeutic agents thus could not account for the difference in nephrotoxicity among the malignancies. Caution is necessary in the interpretation of this finding, however, with further study being warranted to determine the mechanism of renal toxicity apparent selectively in patients with esophageal cancer. Limitations of the present study include possible selection bias of treatment, which is inevitable in a retrospective analysis, and a small sample size for patients with a known serum magnesium concentration and for those who received intravenous magnesium supplementation. Even though all patients treated after July 2011 received magnesium sulfate regardless of their characteristics, cohort effects may still be present that influence the association between magnesium supplementation and <img src=\"http:\/\/www.abmole.com\/upload\/structure\/Triton-x-100.png\" align=\"right\" width=\"287\" style=\"padding:10px;\"\/>nephrotoxicity. In addition, we could not fully assess the incidence and intensity of nonhematologic toxicities in our study as a result of its retrospective nature. Such toxicities, including nausea, vomiting, and <a href=\"http:\/\/www.abmole.com\/products\/talatisamine.html\">Talatisamine<\/a> diarrhea, might be associated with an increased risk for cisplatin-induced nephrotoxicity. Furthermore, comorbidities relevant to inherent nephrotoxicity, such as proteinuria, hypocalcemia, and renal tubular acidosis, were not assessed in the present study. In conclusion, our data have revealed a significant association of cisplatin-induced nephrotoxicity with a relatively poor PS and, to a lesser extent, with the regular use of NSAIDs. Our findings also suggest that magnesium supplementation might be effective for protection against the renal toxicity of cisplatin, a conclusion that should be further addressed in a prospective trial. Polyaminesare present at millimolar concentrations in both prokaryotic and eukaryotic cells and play important roles in cell growth and differentiation. The polyamine content in cells is regulated by biosynthesis, degradation and transport. In Escherichia coli, we thus far reported the properties of <a href=\"http:\/\/www.abmole.com\/products\/glyburide.html\">Glyburide<\/a> several polyamine transport systems. Those are spermidine-preferential and putrescine specific uptake systems as well as PotEand CadB. The former two transport systems function at neutral pH to maintain the optimal concentrations of putrescine and spermidine, whereas the latter two transport systems function at acidic pH to neutralize the external microenvironment and to generate a proton motive force. A spermidine excretion systemalso functions when spermidine over-accumulates in cells. Furthermore, it has been reported that PuuP functions as a putrescine transporter when putrescine is used as an energy source under glucose starvation. In this case, it was necessary to accumulate high concentrations of putrescine in cells. In Saccharomyces cerevisiae, there are four kinds of polyamine uptake proteins, containing either 12 or 16 transmembrane segments.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>With regard to tumor type, we found that individuals with esophageal cancer were at a significantly higher risk for cisplatininduced nephrotoxicity than were those with lung cancer. To our knowledge, such an association has not previously been described. The median dosage of cisplatin in patients with esophageal cancer was 70 mg\/m2, which was not higher &hellip; <a href=\"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/2019\/04\/29\/dur3-sam3-main-contributors-polyamine-uptake-highdose-cisplatin-chemotherapy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DUR3 and SAM3 are the main contributors to polyamine uptake during highdose cisplatin chemotherapy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1077"}],"collection":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/comments?post=1077"}],"version-history":[{"count":1,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1077\/revisions"}],"predecessor-version":[{"id":1078,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/1077\/revisions\/1078"}],"wp:attachment":[{"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/media?parent=1077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/categories?post=1077"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.bioactivescreeninglibrary.com\/index.php\/wp-json\/wp\/v2\/tags?post=1077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}